Murray Stewart
Direktor/Vorstandsmitglied bei X4 PHARMACEUTICALS, INC.
Vermögen: 193 419 $ am 31.05.2024
Profil
Murray Willis Stewart is currently a Director at X4 Pharmaceuticals, Inc., a Director at Vivli Center For Global Clinical Research Data, and a Director at VectivBio AG.
Previously, he served as an Independent Director at Amarin Corp.
Plc, an Independent Director at VectivBio Holding AG, the Chief Medical Officer at Rhythm Pharmaceuticals, Inc., the Chief Medical Officer at GSK Plc, and the Executive VP, Head-Research & Development at Novelion Therapeutics, Inc. Dr. Stewart holds a doctorate degree from The University of Southampton.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
X4 PHARMACEUTICALS, INC.
0,11% | 10.06.2024 | 191 504 ( 0,11% ) | 193 419 $ | 31.05.2024 |
Aktive Positionen von Murray Stewart
| Unternehmen | Position | Beginn |
|---|---|---|
| X4 PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 29.03.2019 |
| Vivli Center For Global Clinical Research Data | Direktor/Vorstandsmitglied | - |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Murray Stewart
| Unternehmen | Position | Ende |
|---|---|---|
| VECTIVBIO HOLDING AG | Direktor/Vorstandsmitglied | 26.06.2023 |
| AMARIN CORPORATION PLC | Direktor/Vorstandsmitglied | 06.03.2023 |
| RHYTHM PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 10.09.2021 |
| NOVELION THERAPEUTICS INC. | Technik-/Wissenschafts-/F&E-Leiter | 17.10.2018 |
| GSK PLC | Technik-/Wissenschafts-/F&E-Leiter | 01.11.2017 |
Ausbildung von Murray Stewart
| The University of Southampton | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| GSK PLC | Health Technology |
| RHYTHM PHARMACEUTICALS, INC. | Health Technology |
| X4 PHARMACEUTICALS, INC. | Health Technology |
| AMARIN CORPORATION PLC | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Novelion Therapeutics, Inc.
 Novelion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelion Therapeutics, Inc. engaged in the development and commercialization of pharmaceuitical products. It focused in providing new standards of care for individuals living with rare diseases. The company was founded on February 3, 1981 and was headquartered in Vancouver, Canada. | Health Technology |
| Vivli Center For Global Clinical Research Data | |
VectivBio Holding AG
 VectivBio Holding AG Pharmaceuticals: MajorHealth Technology VectivBio Holding AG is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of treatments for severe rare conditions with significant unmet medical need. It operates through Switzerland, Canada, and the United States geographical segment. The company was founded by Luca Santarelli on May 22, 2019 and is headquartered in Basel, Switzerland. | Health Technology |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Health Technology |